(IMDZ) - Earnings & Price History

IMDZ: - 4.6, $128.74M, -0.35 (-7.07%)

Sector: Healthcare - Industry: Biotechnology

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The companys products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease

Past IMDZ reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-07AMC-0.575.25.15.355.43.92%-1.89%1.96%152.32K
2016-11-09AMC-0.718.256.756.36.38.4-6.67%▲30.95%22.22%218.50K
2016-08-09AMC-0.686.977.657.516.877.51-1.83%-7.19%-8.89%59.75K
2016-05-10AMC-0.6211.5613.212.5311.4612.84-5.08%-7.74%-12.42%58.22K
2016-03-10AMC-0.5411.5111.1910.7110.7111.83-4.29%7.47%2.86%66.91K
2015-11-12AMC-0.3918.0917.617.3215.5618.21-1.59%▲4.45%2.78%109.89K
2015-08-12AMC-0.4715.1618.9916.1414.0917.13-15.01%-6.07%-20.17%409.09K
2015-05-14BMO-0.6421.2921.7921.3720.1221.96-1.93%-0.37%-2.29%138.30K
2015-03-31AMC-0.6527.2221.1122.6521.7327.737.30%20.18%28.94%444.69K
2014-11-12BMOImmune Design-0.36-0.5530.6729.9429.5829.230.97-1.20%▲3.68%2.44%53.20K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades